Skip to main content


Fig. 1 | BMC Cancer

Fig. 1

From: The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

Fig. 1

CAR T cell therapy. T lymphocytes from the patient or a suitable donor are isolated. Then T cells are activated with anti-human CD3/CD28 antibody-coated beads, anti-CD3 monoclonal antibodies, and/or artificial antigen-presenting cells(APCs). The first, second or third generation CARs are transducted to T cells via a viral or nonviral vector (i.e., eletroporation). Engineered CAR T cells are expanded and infused into the patient who received or not received lymphodepletion regimen

Back to article page